Advantages
- Might be an effective treatment for leaky gut syndrome associated chronic inflammation.
- The novel probiotic induces ethanolamine metabolizing activity thus strengthening the gut barrier.
- Might help evade from several other diseases causes by leaky gut syndrome.
Summary
Leaky gut syndrome is a key source of chronic inflammation, and both are root cause of several human conditions, including inflammatory bowel disease, cancer chemotherapy side effects, diabetes, obesity, CVDs, and aging-related disorders including dementia and others. Leaky gut syndrome is caused due to the reduced capacity to metabolize ethanolamine resulting in ethanolamine accumulation and increasing ARID3a-miR101a-3p activation to reduce tight junctions (Tjp1). The researchers discovered a novel human-origin probiotics called Lactobacillus rhamnosus HL-200 which restores ethanolamine metabolizing capacity and reverse leaky gut and inflammation by restoring ARID3a/miR101a/Tjp1 axis.
The image illustrates the results of the impact of probiotic Lactobacillus rhamnosus HL-200 [HL-200] expression of miR101a-3p (a), Tjp1 (b) and inflammatory markers like IL1β, IL-6 and TNF-α in mice treated with ethanolamine, compared to their control groups. Values presented are mean (n=6-8 mice per group) and error bars as standard error of means. P values with ***<0.001 are statistically significant.
Desired Partnerships
- License
- Sponsored Research
- Co-Development